Published in Blood Weekly, January 19th, 2006
"Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been used to treat bladder cancer for almost 30 years; however, the effector mechanism of the BCG-induced antitumor response remains enigmatic.
"Most BCG research has focused on the mononuclear-cell infiltrate, but growing evidence supports a role for neutrophils in the antitumor response," researchers in the United States report.
According to T.J. Kemp and colleagues at the University of Iowa, "Previously, we demonstrated increased urinary tumor necrosis...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-01-19)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.